The present invention relates to a novel FXR
agonist having a
pyrazine structure, a preparation method therefor and the use thereof, and in particular relates to a compound as represented by the following general formula (I), or a
hydrate, a solvate or a pharmaceutically acceptable salt thereof or a resolved
single isomer thereof, which has the effect of treating non-
alcoholic fatty liver disease.